RESUMO
Objective:To evaluate the effect of modified Shengjiang Powder acupoint application on hypertension patients with phlegm-heat syndrome. Methods:A total of 61 patients in Shijiazhuang hospital of traditional chinese medicine (TCM) meeting the inclusion criteria from September 2018 to September 2019 were randomly divided into two groups, the treatment group was 30 cases, the control group was 31 cases. The control group was given Amlodipine Besylate Tablets orally, and the treatment group added modified Shengjiang Powder acupoint application, and both groups were treated for 4 weeks. TCM syndrome scores were performed before and after treatment, and 24 h ambulatory blood pressure were measured with an ambulatory blood pressure monitor, including daytime mean systolic blood pressure (dMSBP), daytime mean diastolic blood pressure (dMDBP), night time mean systolic blood pressure (nMSBP), and night time mean diastolic blood pressure (nMDBP), 24-hour mean systolic blood pressure (24 hMSBP), 24-hour mean diastolic blood pressure (24 hMDSBP) and blood pressure circadian rhythm detection. Results:After treatment, the nMSBP and 24 hMSBP in the treatment group were significantly lower than those control group ( t values were -2.331,-1.511, P values were 0.045, 0.033), the blood pressure circadian rhythm [(8.87 ± 8.33)% vs. (6.94 ± 6.12)%, t=1.034] of the treatment group was significantly higher than those of the control group ( P<0.05); mdizziness, headache, head wraps, vomiting, sputum salivation, upset, mouth pain, insomnia scores of the treatment group after treatment were significantly lower than those in the control group ( P<0.05). Conclusion:The modified Shengjiang Powder acupoint application can reduce the blood pressure level of hypertension patients with phlegm-heat syndrome, especially for the improvement of night blood pressure, and improve the clinical symptoms.
RESUMO
Objective To explore the clinical effect of Tongluo-Ningxue decoction for hematuria from IgA nephropathy. Methods A total of 60 patients with IgA nephropathy in the hospital between July 2015 and August 2016 were randomly divided into two groups, with 30 cases in each group. The control group was treated with western medicine (Benazepril Hydrochloride plus dipyridamole), whereas the observation group took Tongluo-Ningxue decoction for treatment. The clinical efficacy, clinical symptom score, biochemical index and humoral immune index in the two groups were compared. Results The effective rate was 86.7％ (26/30) in the observation group, and 63.3％ (19/30) in the control group, with the difference between the two groups being statistically significant (χ2=4.356, P=0.037). After treatment, the scores of fatigue and weakness (0.7 ± 0.1 vs. 1.4 ± 0.2, t=18.954), soreness and weakness of waist and knees (0.7 ± 0.1 vs. 1.4 ± 0.2, t=21.071), swollen sore throat (0.6 ± 0.1 vs. 1.4 ± 0.2, t=20.723), and hot flashes and night-time sweating (0.6 ± 01 vs. 1.5 ± 0.2, t=20.732) in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the 24h UP (0.53 ± 0.12 g vs. 0.74 ± 0.15 g, t=5.988), RBC (16.84 ± 5.38 vs. 21.42 ± 9.73, t=2.256), SCr (56.34 ± 7.21 μmol/L vs. 61.27 ± 8.45 μmol/L, t=2.431), and IgA (2.35 ± 0.43 g/L vs. 2.62 ± 0.45 g/L, t=2.376) in the observation group were significantly lower than those in the control group (P<0.05). Conclusions The Tongluo-Ningxue decoction can improve the biochemical indicators, enhance immunity, improve renalfunction and relieve clinical symptoms, and therefore, it is worthwhile for the clinical application.